Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSyncona Share News (SYNC)

Share Price Information for Syncona (SYNC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 110.40
Bid: 110.40
Ask: 111.20
Change: 0.40 (0.36%)
Spread: 0.80 (0.725%)
Open: 110.00
High: 111.20
Low: 110.00
Prev. Close: 110.00
SYNC Live PriceLast checked at -
Syncona is an Investment Trust

To deliver superior long-term capital appreciation from investments in life science businesses, leading long-only and alternative investment funds and managed accounts across multiple asset classes.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TOP NEWS SUMMARY: Novartis agrees to buy UK's Gyroscope Therapeutics

Wed, 22nd Dec 2021 10:51

(Alliance News) - The following is a summary of top news stories Wednesday.

----------

COMPANIES

----------

Novartis confirmed plans to purchase ocular gene therapy company Gyroscope Therapeutics in a deal that could see the Swiss pharmaceuticals firm pay up to USD1.5 billion. Gyroscope Therapeutics is a clinical-stage gene therapy company based in London and specialising in treating eye diseases. An upfront payment of USD800 million will be made as part of the deal, with potential additional milestone payments of up to USD700 million. Basel, Switzerland-based Novartis highlighted that the acquisition complements its expertise in retinal diseases and gene therapy and builds its position in ophthalmology gene therapy and optogenetics. Syncona, a London-listed investor in healthcare companies, has a 54% stake in Gyroscope following a USD42 million investment in March, after co-founding the business in 2016. In a bumper payday, Syncona will receive upfront cash proceeds of GBP334 million from the deal, representing a GBP180 million uplift to the current holding value.

----------

Croda International said it has agreed to sell the majority of its Performance Technologies and Industrial Chemicals businesses to Cargill for an enterprise value of EUR915 million on a cash-free, debt-free basis. Croda said the disposal of the businesses follows the strategic review that it announced in May. The operations being sold represent 77% of PTIC's 2020 revenue and consist of five manufacturing facilities in the UK, China and the Netherlands. "The divestment delivers Croda's transition into a focused Life Sciences and Consumer Care company with these two sectors accounting for well over 90% of the group's 2020 adjusted operating profit following completion," Croda said.

----------

Rio Tinto has agreed to buy the Rincon lithium project in Argentina for USD825 million. The miner said the deal to buy the large undeveloped lithium brine project underscores its commitment to build its battery materials business. The project is a long life, scaleable resource capable of producing battery grade lithium carbonate, it said. "The market fundamentals for battery grade lithium carbonate are strong, with lithium demand forecast to grow 25-35% per annum over the next decade with a significant supply demand deficit expected from the second half of this decade," Rio said. Once bought, Rincon will be subject to studies to confirm the resource, and work will be done to determine the development strategy and timing.

----------

BHP said it will not bump up its offer for Noront Resources to match the one on the table from Wyloo Metals. Earlier in December, Wyloo sweetened its offer for Noront to CAD1.10 per share, which is 47% above BHP's proposal of CAD0.75. Wyloo said the Noront board supported the latest bid. BHP was given the right to match Wyloo's proposal, but on Tuesday said it has decided not to. "BHP is committed to its strict capital discipline framework. While the Eagle's Nest deposit is a promising resource, we do not see adequate long-term value for BHP shareholders to support an increase in BHP's offer in order to match the CAD1.10 per share proposal from Wyloo Metals Pty Ltd," said BHP Chief Development Officer Johan van Jaarsveld.

----------

Beiersdorf has agreed to buy the Chantecaille prestige skin care business. "Through the acquisition of Chantecaille, Beiersdorf will complement its position in the premium skin care segment and seeks to enhance growth in particular in North America and the Asian markets," the Hamburg-based personal-care products retailer said. The enterprise value of the deal is between USD590 million and USD690 million, and it is expected the business generated global sales in excess of USD100 million in 2021. The acquisition is expected to close in the first quarter of 2022.

----------

NatWest's investment bank has plead guilty in US Federal Court to manipulating US Treasuries markets between January 2008 and May 2014. NatWest Markets plead guilty to one count of wire fraud and one count of securities fraud in connection with historical spoofing conduct by former employees. The lender also said the "spoofing" took place during three months in 2018. NatWest will pay USD25.2 million in a criminal fines; about USD2.8 million of criminal forfeiture; and about USD6.8 million in restitution.

----------

Taylor Wimpey has committed to removing terms from contracts that double ground rents for leaseholders every 10 years, the UK Competition & Markets Authority confirmed. Taylor Wimpey said the CMA investigation into the historical sale of leasehold properties with doubling ground rent clauses by the company is closed, following the agreement of voluntary undertakings. The High Wycombe, England-based housebuilder said the cost of the undertakings falls within the original provision Taylor Wimpey made in 2017. By entering into the undertakings there is no finding that Taylor Wimpey has infringed UK consumer law, it noted.

----------

UK property developer Land Securities bought a further stake in the Bluewater shopping mall outside London. Landsec said it has completed the acquisition of an additional 25% share in Bluewater from Lendlease Retail Partnership for GBP172 million, representing a net initial yield of 8.15% and an equivalent yield of 8.25%. In a separate deal, Landsec said it will sell 25% of this share - a 7.5% stake - to co-owner M&G for its pro rata share of the purchase price with the deal completing in April 2022. After this, Landsec's ownership of Bluewater will be 48.8%. Bruce Findlay, managing director of Retail at Landsec said: "We're making this acquisition at a time when retail values and rents are starting to stabilise. Together with our co-owners, we have a clear vision for Bluewater which builds on what is already a thriving retail destination. This investment underlines our strategic commitment to major retail destinations that offer something that can't easily be replicated online."

----------

MARKETS

----------

Equity prices were narrowly mixed in Europe after a mildly positive session in Asia, with little news to drive sentiment. Confirmation that neither the US nor UK will impose lockdowns before Christmas was taken positively. Wall Street was pointed slightly lower ahead of a US gross domestic product reading due at 1330 GMT. "Investors are preparing to go into hibernation for Christmas and will hope by this time next week we’ll know a lot more about the trajectory of Omicron and the likelihood of further restrictions to contain it, and just how long those curbs will be in place," commented Russ Mould, investment director at AJ Bell. Among companies in the news on Wednesday, Novartis shares were down 0.6% in Zurich, while Syncona shares were up 8.6% in London.

----------

CAC 40: up 0.1% at 6,969.30

DAX 40: marginally higher, up 4.42 points at 15,451.86

FTSE 100: marginally lower, down 1.54 points at 7,295.87

----------

Hang Seng: closed up 0.6% at 23,102.33

Nikkei 225: closed up 0.2% at 28,562.21

S&P/ASX 200: closed up 0.1% at 7,364.80

----------

DJIA: called down 0.1%

S&P 500: called down 0.2%

Nasdaq Composite: called down 0.4%

----------

EUR: up at USD1.1285 (USD1.1267)

GBP: up at USD1.3295 (USD1.3248)

USD: up at JPY114.30 (JPY114.14)

Gold: up at USD1,789.34 per ounce (USD1,785.40)

Oil (Brent): up at USD74.37 a barrel (USD73.48)

(currency and commodities changes since previous London equities close)

----------

ECONOMICS AND GENERAL

----------

US President Joe Biden on Tuesday sought to reassure Americans about the country's ability to battle the rapidly spreading Omicron variant, saying it was "prepared" to fight what is now the dominant coronavirus strain in the US. In a televised address, Biden formally announced a raft of new measures to combat the winter surge – including shipping half a billion at home tests – but denied his administration had failed to adequately prepare for the fresh wave of cases. "We should all be concerned about Omicron but not panicked," he said from the White House. "This is not March of 2020," he continued. "Two hundred million people are fully vaccinated. We're prepared, we know more. We just have to stay focused." Biden stressed the country's immunisation campaign would help prevent severe cases among the 62% of the population now fully vaccinated – while scolding the unvaccinated for failing to uphold their "patriotic duty."

----------

Germany's leaders have limited private New Year's parties to 10 people and banned spectators from football games to stem Omicron's spread, stopping short of imposing new coronavirus curbs before Christmas. Speaking after talks with Germany's 16 regional leaders, Chancellor Olaf Scholz said the country was facing "a fifth wave" as the new, highly contagious Omicron variant sweeps the globe. "We are all tired of the pandemic, but that doesn't help us, we must once again stand together," Scholz said as he announced new measures that will affect the vaccinated as well as the unvaccinated. From December 28, Germany will close nightclubs and dance venues, he said. In a bid to avoid large celebrations over New Year's, just 10 people who are vaccinated or have recovered from Covid-19 will be allowed to gather for private parties.

----------

UK Prime Minister Boris Johnson has given the go-ahead for people's Christmas plans, although he warned tougher restrictions could be implemented post-December 25. The prime minister said "continuing uncertainty" about the severity of the Omicron variant and hospital admission rates means he does not believe there is enough evidence at the moment to justify stricter measures. But the situation remains "finely balanced" and people should "exercise caution", Johnson added. In a video message, the prime minister said: "There is no doubt that Omicron continues to surge with a speed unlike anything we've seen before. The situation remains extremely difficult but I also recognise that people have been waiting to hear whether their Christmas plans are going to be affected.

----------

People infected with coronavirus in the UK can now take two lateral flow tests to reduce the self-isolation period from 10 to seven days. The UK Health Security Agency said that those infected with the virus can take two lateral flow tests 24 hours apart on day six and seven of their isolation period, which if negative means they can stop quarantining. The UKHSA said people who leave self-isolation on day seven are strongly advised to limit close contact with other people in crowded or poorly ventilated spaces, and to continue working from home. This comes after analysis by the UKHSA suggested that a seven-day isolation period alongside two negative lateral flow test results had nearly the same protective effect as a 10-day isolation period without testing.

----------

UK economic growth was revised lower in the third quarter on a quarterly basis but higher on an annual basis, figures from the Office for National Statistics showed. On the quarterly before, UK gross domestic product advanced by 1.1% in the three months to September, slower than a 5.4% rise in the three months to July, but missed consensus of an expansion of 1.3%, which would have matched the first estimate. On a year before, the UK economy grew by 6.8% in the third quarter, slowing sharply from the 24% annual growth rate in the second quarter. The latest reading slightly beat the market forecast, cited by FXStreet, of 6.6% annual growth, which also would have matched the first estimate.

----------

Producer prices for the home market in France rose by 3.5% in November from October and by 17% from a year ago, according to official statistics agency Insee.

----------

By Tom Waite; thomaslwaite@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
27 Nov 2023 19:03

TRADING UPDATES: Molten Ventures completes raise; Saietta proposes one

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

Read more
22 Nov 2023 14:30

IN BRIEF: Syncona agrees to buyout deal with Freeline Therapeutics

Syncona Ltd - London-based investor in healthcare companies - Agrees to acquire all remaining stock in investee Freeline Therapeutics Holdings PLC for USD6.50 in cash per share, valuing Freeline at approximately USD28.3 million. Syncona currently owns 49.7% of shares in Freeline. The company will provide up to USD15 million of financing in conjunction with the acquisition to enable Freeline to meet its near-term cash requirements and continue advancing its lead programme FLT201, a potential gene therapy for Gaucher disease.

Read more
16 Nov 2023 10:34

Syncona reports declining asset value as investment head steps down

(Alliance News) - Syncona Ltd on Thursday said net asset value decreased as it swung to a negative return in its latest half year, but that it is well-positioned for future growth thanks to its "rich pipeline".

Read more
16 Nov 2023 08:44

Syncona net asset value falls, co-founder steps down

(Sharecast News) - Life science specialist Syncona reported a net asset value of £1.2bn at the end of its first half on Thursday, down from £1.25bn on 31 March, with a net asset value return of -4.2% during the period.

Read more
14 Nov 2023 11:29

IN BRIEF: Syncona notes investee company's quarterly loss

Syncona Ltd - London-based investor in healthcare companies - Says portfolio company Achilles Therapeutics reports that pretax loss widened to USD16.7 million in the third quarter of 2023 from USD12.4 million the year before, as operating expenses rose 19% to USD19.1 million from USD16.0 million a year ago. Achilles is a Philadelphia, US-based clinical-stage biopharmaceutical company which develops novel cancer immunotherapies. Syncona owns a 25% stake in Achilles.

Read more
9 Nov 2023 15:44

UK earnings, trading statements calendar - next 7 days

Friday 10 November 
Allianz Technology Trust PLCQ3 Results
Wheaton Precious Metals CorpQ3 Results
Monday 13 November 
Bank of Cyprus Holdings PLCQ3 Results
British Land Co PLCHalf Year Results
Kainos Group PLCHalf Year Results
Team Internet Group PLCQ3 Results
Tuesday 14 November 
ActiveOps PLCHalf Year Results
Babcock International Group PLCHalf Year Results
Bank of Georgia Group PLCQ3 Results
Castings PLCHalf Year Results
ConvaTec Group PLCTrading Statement
DCC PLCHalf Year Results
Forterra PLCHalf Year Results
Gear4Music PLCHalf Year Results
Genel Energy PLCTrading Statement
HydrogenOne Capital Growth PLCQ3 Results
Hill & Smith PLCTrading Statement
Imperial Brands PLCFull Year Results
Informa PLCTrading Statement
Land Securities Group PLCHalf Year Results
Oxford Instruments PLCHalf Year Results
Picton Property Income LtdHalf Year Results
Renalytix PLCQ1 Results
Vesuvius PLCTrading Statement
Vodafone Group PLCHalf Year Results
Wise PLCHalf Year Results
Wednesday 15 November 
Diversified Energy Co PLCTrading Statement
Experian PLCHalf Year Results
Fuller, Smith & Turner PLCHalf Year Results
Genuit Group PLCTrading Statement
Intermediate Capital Group PLCHalf Year Results
Ninety One PLC and LtdHalf Year Results
Renold PLCHalf Year Results
SSE PLCHalf Year Results
Synthomer PLCTrading Statement
Tracsis PLCFull Year Results
Tullow Oil PLCTrading Statement
Warehouse REIT PLCHalf Year Results
Thursday 16 November 
Assura PLCHalf Year Results
Atalaya Mining PLCQ3 Results
Aviva PLCTrading Statement
Burberry Group PLCHalf Year Results
Close Brothers Group PLCTrading Statement
CMC Markets PLCHalf Year Results
Crest Nicholson Holdings PLCTrading Statement
Halma PLCHalf Year Results
Great Portland Estates PLCHalf Year Results
Kier Group PLCTrading Statement
International Distributions Services PLCHalf Year Results
Investec PLC and LtdHalf Year Results
Liontrust Asset Management PLCHalf Year Results
Manolete Partners PLCHalf Year Results
Melrose Industries PLCTrading Statement
Norcros PLCHalf Year Results
Premier Foods PLCHalf Year Results
Qinetiq Group PLCHalf Year Results
Spirax-Sarco Engineering PLCTrading Statement
Syncona LtdHalf Year Results
Tatton Asset Management PLCHalf Year Results
Tyman PLCTrading Statement
United Utlities Group PLCHalf Year Results
Young & Co's Brewery PLCHalf Year Results
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
3 Nov 2023 11:51

TRADING UPDATES: Augmentum Fintech makes further investment in Tide

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday, Thursday and Friday and not separately reported by Alliance News:

Read more
18 Oct 2023 12:01

IN BRIEF: Syncona announces takeover offer for Freeline Therapeutics

Syncona Ltd - London-based investor in healthcare companies - Says Syncona Investment Management Ltd has submitted a non-binding proposal to acquire the entire remaining share capital of Freeline Therapeutic Holdings PLC. Offers upfront cash consideration of USD5.00 per American depository share, representing a 20% premium over the USD4.16 volume weighted average price from October 4 to October 16. Syncona currently owns around 57.9% of shares in Stevenage, England-based Freeline, which it co-founded in 2015. Freeline aims to develop gene therapies to treat chronic diseases, most notably its potentially "transformative" FLT201 programme to treat Gaucher disease.

Read more
4 Oct 2023 14:28

Syncona says Freeline and SwanBio clinical trails make progress

(Alliance News) - Syncona Ltd on Wednesday said its portfolio company Freeline Therapeutics Holdings PLC has received positive initial safety, tolerability and enzyme activity data from its FLT201 trial for the treatment of Gaucher disease.

Read more
29 Sep 2023 09:51

IN BRIEF: Syncona launches GBP40 million share buyback programme

Syncona Ltd - London-based investor in healthcare companies - Launches share buyback programme worth up to GBP40.0 million, to be conducted by Numis Securities Ltd. Says core focus remains on allocating capital to portfolio companies' assets. However the buyback is necessary due to Syncona's shares currently trading at a discount to net asset value, which was 184.6 pence per share at June 30. Says buyback will not affect investments into clinical stage assets planned for the next 24 months. Company expects that capital deployment into portfolio and pipeline will total between GBP150 million and GBP200 million for the year ending March 31, in line with prior guidance. Chair Melanie Gee says Syncona "has a high level of confidence in our portfolio and its valuation".

Read more
11 Sep 2023 15:42

Syncona shares slump as Novartis ends eye treatment development

(Sharecast News) - Syncona shares fell as the UK healthcare investment firm said Novartis had stopped the development of experimental eye treatment, GT005, resulting in milestone payments write-off of £54.5m for Gyroscope Holdings in which Syncona once held a 54% stake.

Read more
11 Sep 2023 09:51

Syncona suffers negative valuation hit as Novartis discontinues GT005

(Alliance News) - Syncona Ltd on Monday said it has been informed by Swiss-American pharmaceutical company Novartis AG that the development of eye treatment, GT005, for geographic atrophy secondary to dry age-related macular degeneration will be discontinued.

Read more
11 Sep 2023 07:54

LONDON BRIEFING: Restaurant Group sells Frankie & Benny's and Chiquito

(Alliance News) - Stocks in London are called higher on Monday, ahead of a busy week of interest rate decisions and economic data.

Read more
15 Aug 2023 13:56

IN BRIEF: Syncona notes clinical progress of portfolio firm Freeline

Syncona Ltd - London-based healthcare investor - Notes second quarter results announcement from its Nasdaq-listed portfolio company Freeline Therapeutics Holdings PLC. Says the key highlights include Freeline completing the dosing in the first dose cohort of the phase 1/2 trial of FLT201 in Gaucher disease, following dosing of the second patient. Says initial clinical data from the FLT201 trial is expected in the second half of 2023. Also says Freeline has a cash position of USD38.8 million at June 30 compared to USD55.4 million on March 31, which Freeline expects will enable the company to fund its planned operations into the second quarter of 2024. Freeline says net income in the three months that ended June 30 narrowed to USD14.8 million from USD51.1 million a year earlier.

Read more
10 Aug 2023 09:33

IN BRIEF: Syncona says net asset value slips 1% in first quarter

Syncona Ltd - London-based healthcare investor - Net asset value at June 30 is 184.6 pence per share, down 1.0% from 186.5p on March 31. NAV total return also was negative 1.0% for the recent three months, Syncona's financial first quarter. Notes performance was hurt by "negative foreign exchange movements" across its life science portfolio. This is valued at GBP628.7 million on June 30, up 4.0% from GBP604.6 million on March 31.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.